The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1237
June 19, 2006
View Complete Issue         Table of Contents 2019 
Transdermal Methylphenidates (Daytrana) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Transdermal Methylphenidates (Daytrana) for ADHD
June 19, 2006 (Issue: 1237)
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Methylphenidates (Daytrana) for ADHD
Article code: 1237a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.